Aethlon Medical, Inc.(AEMD)Earnings, Financials & Key Ratios
AEMD•NASDAQ
$2.38
$371480 mkt cap·Price updated May 6, 2026
AboutAethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.Show more
- Revenue$0
- EBITDA-$9M+26.7%
- Net Income-$13M-9.7%
- EPS (Diluted)-85.80-76.5%
- ROE-245.88%-109.8%
- ROIC-911.83%-44.6%
- Debt/Equity0.13-22.2%
- Interest Coverage-924.06
AEMD Key Insights
Aethlon Medical, Inc. (AEMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 37.9% through buybacks
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 15 (bottom 15%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AEMD Price & Volume
Aethlon Medical, Inc. (AEMD) stock price & volume — 10-year historical chart
Loading chart...
AEMD Growth Metrics
Aethlon Medical, Inc. (AEMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-21113.84%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-23.96%
Return on Capital
10 Years-155.4%
5 Years-100.63%
3 Years-113.62%
Last Year-157.31%
AEMD Peer Comparison
Aethlon Medical, Inc. (AEMD) competitors in Renal, dialysis, and blood purification — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 XTLB | 357.58K | 3.25 | -0.34 | -227.72% | -25.53% | 0.03 | ||
 EKSO | 28.63M | 11.80 | -2.40 | -28.6% | -135.66% | -177.4% | 0.29 | |
 PRTH | 430.83M | 5.26 | 7.74 | 8.33% | 5.84% | |||
 TELA | 39.94M | 0.99 | -0.74 | 18.56% | -50.61% | -272.13% | 1.51 | |
 BAX | 8.77B | 16.98 | -9.70 | 5.72% | -9.7% | -16.5% | 1.64 | |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ITGR | 2.97B | 86.29 | 29.86 | 7.57% | 7.67% | 8.23% | 0.80 | |
 MMSI | 3.68B | 61.63 | 28.93 | 11.66% | 9.03% | 8.95% | 0.57 |
Compare AEMD vs Peers
Aethlon Medical, Inc. (AEMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AEMD Income Statement
Aethlon Medical, Inc. (AEMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 392.07K | 149.63K | 229.63K | 650.19K | 659.1K | 294.17K | 574.25K | 0 | 0 | 0 |
| Revenue Growth % | -55.78% | -61.84% | 53.47% | 183.15% | 1.37% | -55.37% | 95.21% | -100% | - | - |
| Cost of Goods Sold | 0 | 2.63B | 3.08B | 0 | 0 | 0 | 0 | 0 | 0 | 391.72K |
| COGS % of Revenue | - | 1761027.23% | 1342674.36% | - | - | - | - | - | - | - |
| Gross Profit | -3.09B▲ 0% | -2.49B▲ 19.5% | -2.85B▼ 14.8% | 650.19K▲ 100.0% | 659.1K▲ 1.4% | 294.17K▼ 55.4% | 574.25K▲ 95.2% | 0▼ 100.0% | 0▲ 0% | -391.72K▲ 0% |
| Gross Margin % | -787423.26% | -1661027.23% | -1242674.36% | 100% | 100% | 100% | 100% | - | - | - |
| Gross Profit Growth % | -118.19% | 19.5% | -14.81% | 100.02% | 1.37% | -55.37% | 95.21% | -100% | - | - |
| Operating Expenses | 6.49M | 4.98M | 6.23M | 6.58M | 8.55M | 10.72M | 12.47M | 12.64M | 9.34M | 2.07B |
| OpEx % of Revenue | 1655.3% | 3328.99% | 2712.68% | 1012.04% | 1297.31% | 3642.53% | 2172.05% | - | - | - |
| Selling, General & Admin | 6.49M | 4.98M | 6.23M | 6.58M | 8.55M | 10.72M | 12.47M | 12.64M | 9.34M | 2.29B |
| SG&A % of Revenue | 1655.41% | 3328.82% | 2712.68% | 1012.04% | 1297.31% | 3642.53% | 2172.05% | - | - | - |
| Research & Development | 673K | 586K | 896K | 927K | 2.07M | 2.34M | 2.75M | 2.52M | 0 | 2.15M |
| R&D % of Revenue | 171.65% | 391.65% | 390.2% | 142.57% | 314.37% | 795.81% | 478.02% | - | - | - |
| Other Operating Expenses | -673.43K | -586K | -896K | -927K | -2.07M | -2.34M | -2.75M | -2.52M | 0 | 0 |
| Operating Income | -6.1M▲ 0% | -4.83M▲ 20.8% | -6M▼ 24.2% | -5.93M▲ 1.2% | -7.89M▼ 33.1% | -10.42M▼ 32.1% | -11.9M▼ 14.2% | -12.64M▼ 6.2% | -9.34M▲ 26.1% | -5.31M▲ 0% |
| Operating Margin % | -1555.32% | -3228.74% | -2612.52% | -912.04% | -1197.31% | -3542.53% | -2072.05% | - | - | - |
| Operating Income Growth % | -39.06% | 20.78% | -24.18% | 1.15% | -33.08% | -32.05% | -14.18% | -6.2% | 26.08% | - |
| EBITDA | -6.07M | -4.8M | -5.97M | -5.9M | -7.85M | -10.3M | -11.66M | -12.28M | -9M | -4.91M |
| EBITDA Margin % | -1547.06% | -3204.91% | -2599.15% | -907.99% | -1191.25% | -3500.48% | -2030.1% | - | - | - |
| EBITDA Growth % | -39.55% | 20.94% | -24.46% | 1.08% | -33% | -31.15% | -13.21% | -5.32% | 26.68% | 48.17% |
| D&A (Non-Cash Add-back) | 32.41K | 35.66K | 30.7K | 26.37K | 39.94K | 123.69K | 240.89K | 359.06K | 339.56K | 391.72K |
| EBIT | -7M | -5.34M | -6M | -5.93M | -7.89M | -10.42M | -11.9M | -12.64M | -13.38M | -9.49M |
| Net Interest Income | -304K | -362K | -220K | -54.23K | -1.58K | 0 | 10.97K | 428.39K | 288.01K | 143K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 10.97K | 428.39K | 298.12K | 153.11K |
| Interest Expense | 304.33K | 361.6K | 220.49K | 54.23K | 1.58K | 0 | 0 | 0 | 10.11K | 10.11K |
| Other Income/Expense | -1.21M | -869K | -220K | -450.05K | 0 | 0 | -131.15K | 428.39K | -4.05M | -4.2M |
| Pretax Income | -7.31M▲ 0% | -5.7M▲ 22.0% | -6.22M▼ 9.1% | -6.38M▼ 2.6% | -7.89M▼ 23.7% | -10.42M▼ 32.1% | -12.03M▼ 15.4% | -12.21M▼ 1.5% | -13.39M▼ 9.7% | -2.03B▲ 0% |
| Pretax Margin % | -1863.68% | -3809.52% | -2708.76% | -981.26% | -1197.31% | -3542.53% | -2094.89% | - | - | - |
| Income Tax | 0 | 0 | -24.79K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0.4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -7.28M▲ 0% | -5.68M▲ 21.9% | -6.2M▼ 9.1% | -6.37M▼ 2.9% | -7.89M▼ 23.7% | -10.42M▼ 32.1% | -12.03M▼ 15.5% | -12.21M▼ 1.5% | -13.39M▼ 9.7% | -2.03B▲ 0% |
| Net Margin % | -1855.78% | -3796.16% | -2697.88% | -980.33% | -1196.58% | -3540.9% | -2094.89% | - | - | - |
| Net Income Growth % | -49.34% | 21.94% | -9.07% | -2.89% | -23.73% | -32.07% | -15.49% | -1.48% | -9.66% | -21113.84% |
| Net Income (Continuing) | -7.31M | -5.7M | -6.22M | -6.38M | -7.89M | -10.42M | -12.03M | -12.21M | -13.39M | -9.5M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -80.97K | -101.25K | -126.03K | -132.12K | -136.91K | -141.71K | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1410.00▲ 0% | -691.70▲ 50.9% | -512.70▲ 25.9% | -186.70▲ 63.6% | -65.20▲ 65.1% | -70.60▼ 8.3% | -58.60▲ 17.0% | -48.60▲ 17.1% | -85.80▼ 76.5% | -2463.47▲ 0% |
| EPS Growth % | -42.64% | 50.94% | 25.88% | 63.58% | 65.08% | -8.28% | 17% | 17.06% | -76.54% | -23.96% |
| EPS (Basic) | -1405.70 | -691.70 | -513.00 | -186.70 | -65.20 | -70.60 | -58.60 | -48.60 | -85.80 | - |
| Diluted Shares Outstanding | 5.18K | 8.21K | 12.08K | 34.15K | 120.9K | 147.6K | 205.4K | 251.3K | 156.08K | 823.13K |
| Basic Shares Outstanding | 5.18K | 8.21K | 12.08K | 34.15K | 120.9K | 147.6K | 205.4K | 251.3K | 156.08K | 823.13K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AEMD Balance Sheet
Aethlon Medical, Inc. (AEMD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.6M | 7.23M | 4.04M | 10.04M | 10.35M | 18.16M | 15.09M | 6.23M | 5.95M | 7.14B |
| Cash & Short-Term Investments | 1.56M | 6.97M | 3.83M | 9.6M | 9.86M | 17.07M | 14.53M | 5.44M | 5.5M | 6.96B |
| Cash Only | 1.56M | 6.97M | 3.83M | 9.6M | 9.86M | 17.07M | 14.53M | 5.44M | 5.5M | 6.96B |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 74.81K | 0 | 206.73K | 149.08K | 127.97K | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | 182.5 | - | 116.05 | 82.56 | 158.78 | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 557.62K | 783.81K | 448.54K | 185.12M |
| Total Non-Current Assets | 129.12K | 121.65K | 84.85K | 346.57K | 317.18K | 1.26M | 2.42M | 2.02M | 1.41M | 915.61M |
| Property, Plant & Equipment | 29.22K | 27.55K | 6.02K | 276.91K | 201.34K | 1.14M | 2.3M | 1.9M | 1.28M | 816.76M |
| Fixed Asset Turnover | 13.42x | 5.43x | 38.14x | 2.35x | 3.27x | 0.26x | 0.25x | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 85K | 75.83K | 66.67K | 57.5K | 56.95K | 2.2K | 1.65K | 1.1K | 550 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 46.73K | 87.51K | 87.51K | 87.51K | 97.81K | 196.26K |
| Other Non-Current Assets | 14.9K | 18.27K | 12.16K | 12.16K | 58.88K | 120.81K | 120.81K | 33.3K | 33.3K | 99.01M |
| Total Assets | 1.73M▲ 0% | 7.35M▲ 325.9% | 4.12M▼ 43.9% | 10.39M▲ 151.9% | 10.67M▲ 2.7% | 19.42M▲ 82.0% | 17.51M▼ 9.8% | 8.25M▼ 52.9% | 7.36M▼ 10.8% | 8.06B▲ 0% |
| Asset Turnover | 0.23x | 0.02x | 0.06x | 0.06x | 0.06x | 0.02x | 0.03x | - | - | 0.00x |
| Asset Growth % | -32.48% | 325.86% | -43.92% | 151.95% | 2.71% | 82% | -9.83% | -52.9% | -10.75% | 123292.6% |
| Total Current Liabilities | 611.76K | 477.96K | 1.82M | 1.07M | 1.38M | 1.82M | 1.51M | 1.83M | 1.9M | 1.26B |
| Accounts Payable | 484.42K | 124.45K | 131.93K | 285.04K | 337.68K | 499.96K | 432.89K | 777.86K | 534.52K | 469.45M |
| Days Payables Outstanding | - | 0.02 | 0.02 | - | - | - | - | - | - | 109.75K |
| Short-Term Debt | 0 | 0 | 962.3K | 0 | 0 | 0 | 0 | 0 | 0 | 330.63M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 100K | 114.85K | 344.55K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 57.87K | 0 | 374.46K | 0 | 595.89K | 0 | 0 | 0 | 178.21K | 926.51M |
| Current Ratio | 2.61x | 15.13x | 2.21x | 9.40x | 7.53x | 9.95x | 10.03x | 3.40x | 3.13x | 3.13x |
| Quick Ratio | 2.61x | 15.13x | 2.21x | 9.40x | 7.53x | 9.95x | 10.03x | 3.40x | 3.13x | 3.13x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 519.2K | 841.15K | 0 | 42.54K | 0 | 602.5K | 939.64K | 649.75K | 336.72K | 86.89M |
| Long-Term Debt | 519.2K | 841.15K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 86.89M |
| Capital Lease Obligations | 0 | 0 | 0 | 42.54K | 0 | 602.5K | 939.64K | 649.75K | 336.72K | 763.89K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -172.12K |
| Total Liabilities | 1.13M | 1.32M | 1.82M | 1.11M | 1.38M | 2.43M | 2.44M | 2.48M | 2.24M | 1.34B |
| Total Debt | 519.2K | 841.15K | 962.3K | 141.1K | 42.54K | 729.41K | 1.21M | 940.32K | 649.75K | 417.52M |
| Net Debt | -1.04M | -6.13M | -2.87M | -9.46M | -9.82M | -16.34M | -13.32M | -4.5M | -4.85M | -6.54B |
| Debt / Equity | 0.87x | 0.14x | 0.42x | 0.02x | 0.00x | 0.04x | 0.08x | 0.16x | 0.13x | 0.13x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -84.96x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1330.54x |
| Interest Coverage | -20.04x | -13.36x | -27.21x | -109.34x | -4994.62x | - | - | - | -924.06x | -939.14x |
| Total Equity | 595.41K▲ 0% | 6.03M▲ 913.2% | 2.3M▼ 61.9% | 9.28M▲ 303.5% | 9.29M▲ 0.2% | 16.99M▲ 82.8% | 15.06M▼ 11.3% | 5.77M▼ 61.7% | 5.12M▼ 11.1% | 6.71B▲ 0% |
| Equity Growth % | -60.37% | 913.21% | -61.89% | 303.53% | 0.18% | 82.83% | -11.34% | -61.72% | -11.15% | 154711.47% |
| Book Value per Share | 115.03 | 734.69 | 190.27 | 271.68 | 76.87 | 115.12 | 73.34 | 22.95 | 32.83 | 8155.61 |
| Total Shareholders' Equity | 676.38K | 6.13M | 2.43M | 9.41M | 9.43M | 17.13M | 15.06M | 5.77M | 5.12M | 6.71B |
| Common Stock | 8.8K | 17.74K | 1.27K | 9.37K | 12.15K | 15.42K | 22.99K | 2.63K | 2.59K | 973K |
| Retained Earnings | -93.78M | -99.46M | -105.65M | -112.03M | -119.91M | -130.33M | -142.36M | -154.57M | -167.95M | -173.22B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | -6.14K | -6.94K | -17.13K | -29.84M |
| Minority Interest | -80.97K | -101.25K | -126.03K | -132.12K | -136.91K | -141.71K | 0 | 0 | 0 | 0 |
AEMD Cash Flow Statement
Aethlon Medical, Inc. (AEMD) cash flow — operating, investing & free cash flow history
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -3.51M | -3.91M | -4.29M | -5.2M | -6.76M | -9.77M | -10.51M | -10.13M | -7.65M | -7.65M |
| Operating CF Margin % | -894.2% | -2613.65% | -1869.76% | -799.4% | -1026.38% | -3320.3% | -1829.38% | - | - | - |
| Operating CF Growth % | 19.02% | -11.55% | -9.79% | -21.06% | -30.15% | -44.38% | -7.56% | 3.57% | 24.52% | -273498.07% |
| Net Income | -7.31M | -5.7M | -6.22M | -6.38M | -7.89M | -10.42M | -12.03M | -12.21M | -13.39M | -2.03B |
| Depreciation & Amortization | 32.41K | 35.66K | 30.7K | 26.37K | 39.94K | 123.69K | 240.89K | 359.06K | 339.56K | 463.45M |
| Stock-Based Compensation | 2.19M | 1.26M | 1.32M | 844K | 779.42K | 750.62K | 1.05M | 1.22M | 415.23K | 217.4M |
| Deferred Taxes | 904.04K | 507.12K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 220.44K | 279.26K | 140.5K | 427.07K | -2.49K | 30.53K | 166.53K | 21.28K | 4.89M | -656.82M |
| Working Capital Changes | 457.63K | -293.66K | 435.88K | -115K | 309.69K | -251.11K | 65.34K | 478.66K | 93.69K | -258.39K |
| Change in Receivables | 199.47K | -74.81K | 74.81K | -206.73K | 57.65K | 21.12K | 127.97K | 0 | 0 | 0 |
| Change in Inventory | 0 | -6.87M | -74.81K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 322.14K | -104.15K | 390.34K | -16.77K | 341.86K | 97.54K | -174.73K | 156.68K | -53.36K | -745.59M |
| Cash from Investing | -16.43K | -24.82K | 0 | -151.66K | -59.88K | -349.19K | -943.11K | -250.87K | 0 | -1.65M |
| Capital Expenditures | -16.43K | -24.82K | 0 | -151.66K | -59.88K | -349.19K | -943.11K | -250.87K | 0 | -1.65M |
| CapEx % of Revenue | 4.19% | 16.59% | - | 23.33% | 9.09% | 118.71% | 164.23% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 2.96M | 9.35M | 1.15M | 11.13M | 7.13M | 17.37M | 8.91M | 1.29M | 7.73M | 6.72B |
| Debt Issued (Net) | 577.46K | 0 | 0 | -992.59K | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | -5.36K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -378.52K | -278.63K | -193.87K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | -40.94K | -132.53K | -88.12K | -12.49K | -34.78K | 4.19M | 6.72B |
| Net Change in Cash | -564.04K▲ 0% | 5.41M▲ 1059.9% | -3.15M▼ 158.1% | 5.78M▲ 283.6% | 303.52K▼ 94.7% | 7.25M▲ 2289.2% | -2.54M▼ 135.0% | -9.09M▼ 258.0% | 69.59K▲ 100.8% | 5.32B▲ 0% |
| Free Cash Flow | -3.52M▲ 0% | -3.94M▼ 11.7% | -4.29M▼ 9.1% | -5.35M▼ 24.6% | -6.82M▼ 27.6% | -10.12M▼ 48.2% | -11.45M▼ 13.2% | -10.38M▲ 9.3% | -7.65M▲ 26.3% | -5.25B▲ 0% |
| FCF Margin % | -898.39% | -2630.24% | -1869.76% | -822.73% | -1035.47% | -3439.01% | -1993.62% | - | - | - |
| FCF Growth % | 18.81% | -11.73% | -9.09% | -24.59% | -27.58% | -48.23% | -13.17% | 9.33% | 26.35% | -61352.01% |
| FCF per Share | -680.49 | -479.27 | -355.33 | -156.65 | -56.45 | -68.54 | -55.74 | -41.31 | -48.98 | -48.98 |
| FCF Conversion (FCF/Net Income) | 0.48x | 0.69x | 0.69x | 0.82x | 0.86x | 0.94x | 0.87x | 0.83x | 0.57x | 2.59x |
| Interest Paid | 0 | 0 | 0 | 83.33K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AEMD Key Ratios
Aethlon Medical, Inc. (AEMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -693.69% | -171.39% | -148.71% | -110.12% | -84.94% | -79.25% | -75.06% | -117.21% | -245.88% | -30.21% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -12703.34% | -747.19% | -630.78% | -911.83% | -911.83% |
| Gross Margin | -787423.26% | -1661027.23% | -1242674.36% | 100% | 100% | 100% | 100% | - | - | - |
| Net Margin | -1855.78% | -3796.16% | -2697.88% | -980.33% | -1196.58% | -3540.9% | -2094.89% | - | - | - |
| Debt / Equity | 0.87x | 0.14x | 0.42x | 0.02x | 0.00x | 0.04x | 0.08x | 0.16x | 0.13x | 0.13x |
| Interest Coverage | -20.04x | -13.36x | -27.21x | -109.34x | -4994.62x | - | - | - | -924.06x | -939.14x |
| FCF Conversion | 0.48x | 0.69x | 0.69x | 0.82x | 0.86x | 0.94x | 0.87x | 0.83x | 0.57x | 2.59x |
| Revenue Growth | -55.78% | -61.84% | 53.47% | 183.15% | 1.37% | -55.37% | 95.21% | -100% | - | - |
AEMD Frequently Asked Questions
Aethlon Medical, Inc. (AEMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aethlon Medical, Inc. (AEMD) grew revenue by 0.0% over the past year. Growth has been modest.
Aethlon Medical, Inc. (AEMD) reported a net loss of $2.03B for fiscal year 2025.
Dividend & Returns
Aethlon Medical, Inc. (AEMD) has a return on equity (ROE) of -245.9%. Negative ROE indicates the company is unprofitable.
Aethlon Medical, Inc. (AEMD) had negative free cash flow of $5.25B in fiscal year 2025, likely due to heavy capital investments.
Explore More AEMD
Aethlon Medical, Inc. (AEMD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates